Bavarian Nordic received a new supply order from Janssen Pharmaceutica NV to manufacture and deliver bulk drug substance of MVA-BN Filo vaccine to treat Ebola.
The MVA-BN Filo vaccine will be licensed to Janssen as part of its Ebola vaccine regimen, Zabdeno and Mvabea, which the European Commission approved in 2020. The supply order is valued at approximately $28 million.
Manufacturing of the bulk drug substance will begin in May, with delivery expected to take place in the second half of 2021. To enable rapid manufacturing of this order, some of the planned batches of JYNNEOS smallpox vaccine bulk drug substance will be delayed into 2022.
“We are pleased to continue to supply Ebola vaccines for populations at risk. As we are currently working to expand our bulk manufacturing capabilities creating a center of excellence in vaccine manufacturing, we are pleased that other customers have shown flexibility, allowing us to quickly respond to urgent public health needs in the fight against emerging infectious diseases like Ebola,” Paul Chaplin, president & CEO of Bavarian Nordic, said.
Bavarian Nordic is a company focused on the development, manufacture, and commercialization of life-saving vaccines. The company is a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, JYNNEOS.
Janssen Pharmaceutica NV is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.